Taft Pharmaceutical Litigation partner Andrew Alul was quoted in two recent Bloomberg BNA Pharmaceutical Law & Industry Report articles “Roche, Ariosa Defeat Illumina on Prenatal DNA Test Patents,” on Dec. 26 and “Endo Patent Decision Appeal May Shift Life Sciences Investment,” on Dec. 6.

Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.